Similar articles for PMID: 21663839

Year	Number of Results
1996	3
1997	6
1998	10
1999	11
2000	9
2001	12
2002	5
2003	3
2004	3
2005	8
2007	1
2008	5
2009	4
2010	1
2011	6
2013	1
2014	1
2015	2
2016	3
2017	2
2019	2
2020	1
2021	1
2024	0

1

Molecular mechanisms for insulin resistance in treated HIV-infection.

Hruz PW. Hruz PW. Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):459-68. doi: 10.1016/j.beem.2010.10.017. Best Pract Res Clin Endocrinol Metab. 2011. PMID: 21663839 Free PMC article. Review.

2

Standard treatments for HIV, Spring 1997.

Smith D. Smith D. AIDS Treat News. 1997 Apr 18;(No 269):4-5. AIDS Treat News. 1997. PMID: 11364255

3

Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.

Patel N, Abdelsayed S, Veve M, Miller CD. Patel N, et al. Ann Pharmacother. 2011 Mar;45(3):317-24. doi: 10.1345/aph.1P576. Epub 2011 Mar 8. Ann Pharmacother. 2011. PMID: 21386025

4

[Role of etravirine in combination antiretroviral therapy].

Domingo P. Domingo P. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:46-51. doi: 10.1016/S0213-005X(09)73219-7. Enferm Infecc Microbiol Clin. 2009. PMID: 20116628 Review. Spanish.

5

The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Noor MA. Noor MA. Curr HIV/AIDS Rep. 2007 Aug;4(3):126-34. doi: 10.1007/s11904-007-0019-4. Curr HIV/AIDS Rep. 2007. PMID: 17883998 Review.

6

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

Carr A, Miller J, Law M, Cooper DA. Carr A, et al. AIDS. 2000 Feb 18;14(3):F25-32. doi: 10.1097/00002030-200002180-00001. AIDS. 2000. PMID: 10716495 Clinical Trial.

7

[Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].

Espiau M, Soler-Palacín P, Borrull A, Figueras C. Espiau M, et al. Enferm Infecc Microbiol Clin. 2011 Apr;29(4):319. doi: 10.1016/j.eimc.2010.11.009. Epub 2011 Feb 18. Enferm Infecc Microbiol Clin. 2011. PMID: 21334110 Spanish. No abstract available.

8

[Lipid disorders in patients with HIV-induced diseases].

Chanu B, Valensi P. Chanu B, et al. Presse Med. 2005 Sep 10;34(15):1087-94. doi: 10.1016/s0755-4982(05)84124-7. Presse Med. 2005. PMID: 16334888 Review. French.

9

Nonnucleoside reverse transcriptase inhibitors.

Murphy RL. Murphy RL. AIDS Clin Care. 1997 Oct;9(10):75-7, 79. AIDS Clin Care. 1997. PMID: 11364757

10

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.

Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Boyd MA, et al. Lancet HIV. 2017 Jan;4(1):e13-e20. doi: 10.1016/S2352-3018(16)30189-8. Epub 2016 Nov 1. Lancet HIV. 2017. PMID: 27815068 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

99 results

Results by year